<DOC>
	<DOCNO>NCT00781547</DOCNO>
	<brief_summary>The overall aim study investigate effect GH treatment men Metabolic Syndrome high risk develop type 2 DM . Forty men abdominal obesity impair glucose tolerance randomize two parallel treatment group GH placebo 12 month . The subject receive treatment recombinant human GH ( Genotropin® ) placebo administer daily s.c. injection bedtime . The initial dose GH 0.4 IU per day increase 0.8 IU 2 week 1.2 IU 4 week treatment . Thus , target dose 1.2 IU per day resembles approximately 0.015 IU/kg/day . The GH dose reduce half event side-effects . Oral write instruction term administration dosage give . The treatment discontinue patient . The treatment discontinue malignancy discover , DM develop , subject experience cerebrovascular disease event side-effects consider serious . The treatment code subject include trial keep Sahlgrenska University Hospital Pharmacy . This code broken request investigator . Compliance assess collect empty vial study subject . The treatment discontinue end study .</brief_summary>
	<brief_title>Growth Hormone Treatment Men With High Risk Developing Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Fasting plasma glucose level ≥ 6.1 ≤ 7.8 mmol/L ( IFG ) and/or plasma glucose 2 hour 75g oral glucose load 6.911.0 mmol/L ( IGT ) . BMI &gt; 25 kg/m2 . Waist/hip ratio &gt; 0.95 Proliferative diabetic retinopathy . Macroalbuminuri and/or serum creatinine &gt; 150mmol/L Known ischemic heart disease , previous stroke claudicatio intermittence . Known malignancy . Other hormonal therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>growth hormone</keyword>
	<keyword>obesity</keyword>
	<keyword>abdominal obesity</keyword>
</DOC>